The effects of a novel, modified p-cyclodextrin (SBE4-p-CD; a variably substituted sulfobutyl ether with an average degree of substitution of four) on eye irritation and miotic response of an ophthalmically applied pilocarpine prodrug, 0,0'-dipropionyl-(l,4-xylylene) bispilocarpate, in albino rabbits were studied. Compared to the commercial pilocarpine eyedrop solution (163 mM, equivalent to 3.4% pilocarpine), 12-24 mM pilocarpine prodrug solutions (equivalent to 0.5 -1.0% pilocarpine, respectively) decreased peak miotic intensity (I max ) and increased the time to reach peak (t max ), but did not significantly affect values for the area under the miosis versus time curves (AUC), i.e. 12 -24 mM pilocarpine prodrug appeared to be equivalent to 163 mM pilocarpine. Ocularly applied 12-24 mM pilocarpine prodrug solutions, however, were more irritating than a commercial pilocarpine eyedrop solution. Coadministered SBE4-p-CD significantly decreased the eye irritation of the pilocarpine prodrug solutions. Coadministered SBE4-P-CD did not affect the miotic response of prodrug solution when the molar ratio of SBE4-p-CD to prodrug was low. However, increasing the molar ratio of SBE4-p-CD to prodrug decreased the I max and AUC values. The results show that eye irritation of the pilocarpine prodrug is prevented by levels of SBE4-P-CD that do not affect the apparent ocular absorption of the prodrug.